Granted Patent B2

US 12,410,475 · App. 17/751,201 · Granted Sep 9, 2025

Inventors: Taylor Jacob Jensen (San Diego, CA); Jennifer Geis (San Diego, CA); Sung Kyun Kim (San Diego, CA); Cosmin Deciu (San Diego, CA); Mathias Ehrich (San Diego, CA)

Assignee: Sequenom, Inc.

C12Q1/6883G16B25/00G16B25/10G16B25/20G16B45/00C12Q2537/143C12Q2565/627C12Q2600/106C12Q2600/158C12Q2600/16H01J49/164

Abstract

Claims (33)

1. A method for detecting one, two, three or four copies of a fetal chromosome or portion thereof in a sample, comprising:

(a) contacting a sample comprising circulating cell-free nucleic acid from a human pregnant female bearing a fetus with a methylation sensitive restriction enzyme under cleavage conditions to selectively digest non-methylated maternal nucleic acid from target polynucleotides in each of chromosomes 13, 18 and 21;

(b) the steps of: (i) contacting the nucleic acid of step (a) with a collection of four sets of primer pairs under amplification conditions, wherein at least one of each primer pair is specific for nucleic acid sequences located within at least one of the target polynucleotides in chromosome 13, chromosome 18 and chromosome 21, and one of the four sets of primer pairs is specific for amplifying the target polynucleotide from one of chromosomes 13, 18 or 21, thereby generating amplicons from the target polynucleotides from the undigested polynucleotide targets, wherein the target polynucleotides are in:

chromosome 13 polynucleotides of SEQ ID NOs: 198 and 211, or a complement thereof;

chromosome 18 polynucleotides of SEQ ID NOs: 229 and 231, or a complement thereof; and

chromosome 21 polynucleotides of SEQ ID NOs: 244 and 252, or a complement thereof; thereby generating amplicons; and

(ii) contacting the sample with at least one competitor oligonucleotide under the amplification conditions such that a competitor amplicon comprising the competitor oligonucleotide is generated, wherein the competitor oligonucleotide comprises a sequence substantially identical to a first target sequence but includes at least one nucleotide substitution;

(c) determining an amount of the chromosome 13, chromosome 18 and chromosome 21 amplicons in (b) by comparing a ratio of the first target amplicon to the at least one competitor amplicon; and

(d) determining, based on the relative amounts of target amplicons from step (c), whether there is one, two, three or four copies of one or more of chromosome 13, chromosome 18, and chromosome 21, or a portion thereof, in the fetus.

2. The method of claim 1 , wherein the amounts of the target amplicons and the at least one competitor amplicon are determined by a process comprising mass spectrometry.

3. The method of claim 1 , wherein the amounts of the target amplicons and the at least one competitor amplicon are determined by a process comprising sequencing.

4. The method of claim 1 , wherein the amounts of the target amplicons and the at least one competitor amplicon are determined by quantitative PCR.

5. The method of claim 1 , wherein the amplification is performed as a single multiplex reaction.

6. The method of claim 1 , wherein the primer pairs comprise polynucleotides chosen from SEQ ID NOs: 6, 70, 19, 83, 37, 101, 39, 103, 52, 116, 60, 124, or a complement thereof.

7. The method of claim 1 , wherein the competitor oligonucleotides each comprise a polynucleotide chosen from SEQ ID NOs: 262, 275, 293, 295, 308, 316, or a complement thereof.

8. The method of claim 1 , wherein (b) comprises contacting the target amplicons and the at least one competitor amplicon with extension oligonucleotides under conditions in which the extension oligonucleotides anneal to the target amplicons and the at least one competitor amplicon and are extended by one or more nucleotides to generate extended amplicons.

9. The method of claim 8 , wherein each of the extension oligonucleotides comprises a polynucleotide chosen from SEQ ID NOs: 134, 147, 165, 167, 180, 188, or a complement thereof.

10. The method of claim 1 , further comprising determining in (b) (a) the amounts of target polynucleotides in:

chromosome 13 polynucleotides of SEQ ID NOs: 199, 205, or 207 or a complement thereof;

chromosome 18 polynucleotides of SEQ ID NO: 219 or a complement thereof; and

chromosome 21 polynucleotides of SEQ ID NOs: 233, 235, 237, 241, 247, or 254 or a complement thereof.

11. The method of claim 10 , wherein the primer pairs comprise polynucleotides chosen from SEQ ID NOs: 7, 71, 13, 77, 15, 79, 27, 91, 41, 105, 43, 107, 45, 109, 49, 113, 55, 119, 62, 126 or a complement thereof.

12. The method of claim 1 , wherein the competitor oligonucleotides each comprise a polynucleotide chosen from SEQ ID NOs: 263, 269, 271, 283, 297, 299, 301, 305, 311, 318 or a complement thereof.

13. The method of claim 10 , wherein (b) comprises contacting the target amplicons and the at least one competitor amplicon with extension oligonucleotides under conditions in which the extension oligonucleotides anneal to the target amplicons and the at least one competitor amplicon and are extended by one or more nucleotides to generate extended amplicons.

14. The method of claim 13 , wherein each of the extension oligonucleotides comprises a polynucleotide chosen from SEQ ID NOs: 135, 141, 143, 155, 169, 171, 173, 177, 183, 190 or a complement thereof.

15. The method of claim 1 , further comprising determining in (b) the amounts of target polynucleotides in:

chromosome 13 polynucleotides of SEQ ID NOs: 193-197, 200-204, 206, 208, 210, 212-213, and 215, or a complement thereof;

chromosome 18 polynucleotides of SEQ ID NO: 216-218, 220-221, 223-228, and 230, or a complement thereof; and

chromosome 21 polynucleotides of SEQ ID NOs: 234, 236, 238-240, 242-243, 245-246, 248-251, and 255, or a complement thereof.

16. The method of claim 15 , wherein the primer pairs comprise polynucleotides chosen from SEQ ID NOs: 1, 65, 2, 66, 3, 67, 4, 68, 5, 69, 8, 72, 9, 73, 10, 74, 11, 75, 12, 76, 14, 78, 16, 80, 18, 82, 20, 84, 21, 85, 23, 87, 24, 88, 25, 89, 26, 90, 28, 92, 29, 93, 31, 95, 32, 96, 33, 97, 34, 98, 35, 99, 36, 100, 38, 102, 42, 106, 44, 108, 46, 110, 47, 111, 48, 112, 50, 114, 51, 115, 53, 117, 54, 118, 56, 120, 57, 121, 58, 122, 59, 123, 63, 127, or a complement thereof.

17. The method of claim 15 , wherein the competitor oligonucleotides each comprise a polynucleotide chosen from SEQ ID NOs: 257, 258, 259, 260, 261, 264, 265, 266, 267, 268, 270, 272, 274, 276, 277, 279, 280, 281, 282, 284, 285, 287, 288, 289, 290, 291, 292, 294, 298, 300, 302, 303, 304, 306, 307, 309, 310, 312, 313, 314, 315, 319, or a complement thereof.

18. The method of claim 15 , wherein (b) comprises contacting the target amplicons and the at least one competitor amplicon with extension oligonucleotides under conditions in which the extension oligonucleotides anneal to the target amplicons and the at least one competitor amplicon and are extended by one or more nucleotides to generate extended amplicons.

19. The method of claim 18 , wherein each of the extension oligonucleotides comprises a polynucleotide chosen from SEQ ID NOs: 129, 130, 131, 132, 133, 136, 137, 138, 139, 140, 142, 144, 146, 148, 149, 151, 152, 153, 154, 156, 157, 159, 160, 161, 162, 163, 164, 166, 170, 172, 174, 175, 176, 178, 179, 181, 182, 184, 185, 186, 187, 191, or a complement thereof.

Assignments (1)

Continuity (3)

References Cited (400)